RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma

Abstract Background Severe hypoxia is a prominent character of pancreatic ductal adenocarcinoma (PDAC) microenvironment. In the process of gemcitabine based chemotherapy, PDAC cells are insulted from replication stresses co-induced by hypoxia and gemcitabine. However, PDAC cells get outstanding abil...

Full description

Bibliographic Details
Main Authors: Qiu Tu, Xiuyun Liu, Xiaoqing Yao, Ruixue Li, Gaojing Liu, Honglv Jiang, Kaiqin Li, Qiongfang Chen, Xiaoyan Huang, Qing Chang, Guoqiang Xu, Hong Zhu, Peng Shi, Bo Zhao
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
RETSAT
DDX39B
Fork restarting
Hypoxia
Gemcitabine
Resistance
Online Access:https://doi.org/10.1186/s13046-022-02490-3

Similar Items

Similar Items